ClinicalTrials.gg
RecruitingNCT02936232Updated Nov 24, 2023

Severe Sepsis and Septic Shock Registry

An observational study in Sepsis, sponsored by Seoul National University Hospital. Recruiting at 3 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by Seoul National University Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Sepsis with a site in Korea, Republic of — 9 open to participants now, 9 under way, none of them phase 3. Sepsis · Korea, Republic of.

Planned enrollment
Largest of 11
3,000 · median 245
Started
2014
with 2 others
Observational
11 of 31
7 open now
Registered
16th of 31
by date
Lead sponsor
6 of 31
Seoul National University Hospital

Among the 31 studies in Sepsis with a site in Korea, Republic of, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2014, is one of 11 observational ones, and was the 16th registered.

Sepsis

2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.

Browse Sepsis studies →

Open to participants now

9 of the 31 studies in Sepsis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Sepsis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The aim of this study is to construct multi-center sepsis registry that can be used for data warehousing and clinical research.

Read the detailed description

This registry prospectively enrolls adult patients with severe sepsis or septic shock in 21 tertiary hospital emergency departments.

Registered data can be used for quality control and clinical research to reduce sepsis-related mortality.

03

Conditions studied

  • Sepsis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with severe sepsis or septic shock

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • two of more systemic inflammatory reaction syndrome criteria fever > 38.3 'C or hypothermia \< 36'C, tachycardia over 90 bpm tachypnea over 20 per minute, leukocytosis (WBC over 12k/microL) or leukopenia (WBC below 4k/microL)
  • suspected or proven infection
  • any organ dysfunction as follows:

    1. cardiovascular (hypotension, systolic blood pressure \<90 mmHg, mean arterial pressure \<70mmHg)
    2. tissue hypoperfusion (lactate above upper limits laboratory normal)
    3. acute lung injury (PaO2/inspired oxygen fraction \< 250 in the absence of pneumonia, PaO2/inspired oxygen fraction \< 200 in the presence of pneumonia)
    4. acute kidney injury (Urine output \< 0.5mL/kg/hr for at least 2 hrs Serum creatinine > 2.0 mg/dL)
    5. acute liver injury (Total > 2mg/dL)
    6. acute coagulopathy ( count \< 100,000/μL or , international normalized ratio > 1.5)

Exclusion criteria

Exclusion Criteria:

  • age less than 18 years old
  • patients with cardiac arrest at presentation
  • patients with advanced directives not to deliver aggressive organ supportive management
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. 28-day mortality

    According to hospital discharge record review and telephone follow-up.

    Time frame: 28-day

Secondary outcomes

  1. 90-day mortality

    According to hospital discharge record review and telephone follow-up.

    Time frame: 90-day

  2. Organ support treatment (mechanical ventilation)

    According to hospital record review

    Time frame: hospital discharge (non-survivors) or 90 days (survivors)

  3. Organ support treatment (renal replacement therapy)

    According to hospital record review

    Time frame: hospital discharge (non-survivors) or 90 days (survivors)

  4. ICU length of stay

    According to hospital record review

    Time frame: hospital discharge (non-survivors) or 90 days (survivors)

  5. Hospital length of stay

    According to hospital record review

    Time frame: hospital discharge (non-survivors) or 90 days (survivors)

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Mar 2028 and a completion of Mar 2028. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2016
First posted
Oct 18, 2016
Start
Aug 2014
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02936232
Collaborators
Seoul National University Bundang Hospital, Seoul National University Boramae Hospital, Hallym University Kangnam Sacred Heart Hospital, Gangnam Severance Hospital, Kyungpook National University Hospital, Kyunghee University Medical Center, Korea University Guro Hospital, Korea University Anam Hospital, The Catholic University of Korea, Samsung Medical Center, Asan Medical Center, Severance Hospital, Ulsan University Hospital, Inje University Ilsan Paik Hospital, Chonnam National University Hospital, Chonbuk National University Hospital, Jeju National University Hospital, Chosun University Hospital, Hallym University Medical Center, Hanyang University Seoul Hospital, Bucheon St. Mary's Hospital
Responsible party
Gil Joon Suh (Professor, Seoul National University Hospital) — Principal investigator
First posted
Oct 18, 2016
Start date
Aug 2014
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 24, 2023

Study contacts

Kyung Su Kim, MD, PhD
Contact
kanesu@gmail.com
82-10-8033-1127
Woon Wong Kwon, MD, PhD
Contact
kwy711@hanmail.net
82-2-2072-4751
Gil Joon Suh, MD, PhD
study director · Seoul National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion